These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9549638)

  • 21. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.
    Murdoch D; McTavish D
    Drugs; 1992 Jan; 43(1):123-40. PubMed ID: 1372856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.
    Wagstaff AJ; Davis R; McTavish D
    Drugs; 1996 May; 51(5):777-91. PubMed ID: 8861547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fosinoprilat alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes.
    Yang S; Li R; Qu X; Tang L; Ge G; Fang W; Qiao Z; Ma J; Hou Y; Liu H
    Cell Immunol; 2013; 284(1-2):182-6. PubMed ID: 24036412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
    Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing.
    K Gupta S; Kantesaria B; Glue P
    Drug Discov Ther; 2014 Apr; 8(2):89-95. PubMed ID: 24815584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
    Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
    Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors.
    Ranadive SA; Chen AX; Serajuddin AT
    Pharm Res; 1992 Nov; 9(11):1480-6. PubMed ID: 1475237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of fosinopril sodium in healthy subjects.
    Singhvi SM; Duchin KL; Morrison RA; Willard DA; Everett DW; Frantz M
    Br J Clin Pharmacol; 1988 Jan; 25(1):9-15. PubMed ID: 2967089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
    Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
    Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic dependent disposition of the angiotensin converting enzyme inhibitor, libenzapril.
    Kochak GM; Choi RL; deSilva JK; Reydel-Bax P
    J Clin Pharmacol; 1990 Feb; 30(2):138-43. PubMed ID: 2312764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients.
    Zhao Y; Duan JL; Wu XM; Jiang JY; Lu W; Zhang LP; Wang J; Meng XL; Xu CY; Jia DL; Liu W; Sheng XY
    Chin Med J (Engl); 2009 Sep; 122(17):1979-84. PubMed ID: 19781381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
    Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
    Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative Assessment of the Effect of Chronic Kidney Disease on the Nonrenal Clearance of 10 Drugs After Intravenous Administration.
    Hinderling PH; Yu Y
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):138-151. PubMed ID: 30589517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of metabolites of fosinopril produced by human and rat liver microsomes with liquid chromatography-mass spectrometry.
    Uutela P; Monto M; Iso-Mustajärvi I; Madetoja M; Yliperttula M; Ketola RA
    Eur J Pharm Sci; 2014 Mar; 53():86-94. PubMed ID: 24365260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics of angiotensin-converting enzyme inhibitors in renal failure.
    Sica DA
    J Cardiovasc Pharmacol; 1992; 20 Suppl 10():S13-20. PubMed ID: 1283426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.
    Smithers JA; Kulmala HK; Thompson GA; Antony KK; Lewis EW; Ruberg SJ; Kenny MT; Dulworth JK; Brackman MA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):115-20. PubMed ID: 1534211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetics and safety of eptifibatide in healthy Chinese volunteers and simulations on the dose regimens approved for a Western population.
    Wang XP; Zhou ZL; Yang M; Mai LP; Zheng ZJ; He GD; Wu YH; Lin QX; Shan ZX; Yu XY
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):658-66. PubMed ID: 26104033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fosinopril. A review of its pharmacology and clinical efficacy in the management of heart failure.
    Davis R; Coukell A; McTavish D
    Drugs; 1997 Jul; 54(1):103-16. PubMed ID: 9211084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.